<DOC>
	<DOCNO>NCT00003139</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs pilocarpine may protect normal cell side effect radiation therapy . It yet know pilocarpine may effective prevent mucositis dry mouth patient receive radiation therapy head neck cancer . PURPOSE : Randomized , double-blinded , phase III trial study effectiveness pilocarpine prevent mucositis dry mouth patient receive radiation therapy head neck cancer .</brief_summary>
	<brief_title>Pilocarpine Preventing Mucositis Dry Mouth Patients Receiving Radiation Therapy Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether prophylactic use pilocarpine shelter unstimulated stimulated whole salivary flow patient head neck cancer . II . Determine whether prophylactic use pilocarpine moderate xerostomia patient . III . Determine whether prophylactic use pilocarpine reduce grade duration radiation induce mucositis patient . IV . Evaluate quality life outcomes patient receive pilocarpine versus placebo . V. Evaluate impact xerostomia patient receive irradiation head neck . OUTLINE : This randomize , double blind study . Patients receive central axis midplane dose radiotherapy five day per week 6 7 week . Oral pilocarpine placebo administer begin 3 day prior radiotherapy , one tablet four time per day three month . A tablet take 45-60 minute radiotherapy . After three month , 3-4 day rest period , patient receive non blind pilocarpine additional three month period . Patients follow week 4 , 13 , 26 start radiotherapy . PROJECTED ACCRUAL : A total 244 patient accrue ( 122 per treatment arm ) .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven oral cavity and/or oropharyngeal squamous cell carcinoma Radiation volume encompass least 50 % parotid gland least 50 Gy deliver volume via external beam No salivary gland malignancy diseases PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 60100 % Life Expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Effective contraceptive method must use study No pilocarpine allergy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck Surgery : Not specify Other : No concurrent adrenergic antagonist , cholinergic drug , anticholinergic , tricyclic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>oral complication</keyword>
	<keyword>lip oral cavity squamous cell carcinoma</keyword>
	<keyword>oropharyngeal squamous cell carcinoma</keyword>
</DOC>